Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs

Acta Anaesthesiologica Scandinavica

Volumn 46, Issue 3, 2002, Pages 297-302

  Hirota, K ^a   Yoshioka, H ^a   Kabara, S ^a   Koizumi, Y ^a   Abe, H ^a   Sato, T ^a   Matsuki, A ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Bronchoconstriction; Colforsin daropate; Pulmonary hypertension; Serotonin

Indexed keywords

AMINOPHYLLINE; CATECHOLAMINE; COLFORSIN DAROPATE; CYCLIC AMP; FORSKOLIN DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PROPRANOLOL; PROSTAGLANDIN E1; SEROTONIN; SPASMOLYTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DILATATION; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHODILATATION; BRONCHOSPASM; CATECHOLAMINE BLOOD LEVEL; CELL LEVEL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC CIRCULATION;

ANIMALS; BRONCHIAL SPASM; BRONCHOCONSTRICTION; CATECHOLAMINES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; HYPERTENSION, PULMONARY; PARASYMPATHOLYTICS; PULMONARY CIRCULATION; SEROTONIN; SEROTONIN ANTAGONISTS; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 0036210952     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2002.t01-1-460312.x     Document Type: Article

References (23)

1. Milrinone attenuates serotonin-induced pulmonary hypertension and broncho-constriction in dogs
2. Comparison of the spasmolytic effects of olprinone and aminophylline on serotonin-induced pulmonary hypertension and broncho-constriction with or without β-blockade in dogs
3. 1 on serotonin-induced bronchoconstriction and pulmonary hypertension in dogs
4. Comparative effects of enoximone and theophylline on plasma catecholamines and haemodynamics in cardiosurgical patients
5. Stimulation of endogenous catecholamine release by theophylline: A proposed additional mechanism of action for theophylline effects
6. Forskolin effects on slow inward current and phasic tension of frog atrial fibres: Modulation by adenosine and phosphodiesterase inhibitors
7. Improvement of drug-induced cardiac failure by NKH477, a novel forskolin derivative, in the dog heart-lung preparation
8. Cardiovascular and adenylate cyclase stimulant properties of NKH477, a novel water-soluble forskolin derivative
9. NKH477: A new inotropic agent
10. Clinical trial of NKH477 in patients with acute heart failure: A multicenter group study
11. Acute effect of NKH477, a novel forskolin derivative, in patients with acute heart failure: A multicenter placebo-controlled double-blind trial
12. 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists
13. Species differences in the responses of pulmonary vascular preparations to 5-hydroxytryptamine
14. Increased plasma serotonin in primary pulmonary hypertension
15. High plasma serotonin levels in primary pulmonary hypertension. Effects of long-term epoprostenol (prostacyclin) therapy
16. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension
17. Fenfluramine-induced pulmonary vasoconstriction, role of serotonin receptors and potassium channels
18. Metabolic fate of NKH477. (1) Blood and plasma concentrations, distribution and excretion in rats and dogs after a single intravenous administration
19. Bronchial vs cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog
20. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle
21. Effects of NKH477, a forskolin derivative, and dibutyryl-cyclic AMP on adrenal catecholamine release in response to splanchnic nerve stimulation, acetylcholine, DMPP and muscarine in anesthetized dogs
22. Bronchial hyperresponsiveness and anesthesia: Physiologic and therapeutic perspectives
23. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists